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Abstract: The progestational steroid norgestrel was synthesized and tested between 1960 and 1965 
through an international cooperation between Wyeth, USA and Schering, Berlin. It is a mixture of 
two “enantiomers,” with only one form (designated as levonorgestrel) biologically active. When 
taken orally, it is rapidly absorbed, not subjected to a “first-pass” effect and is approximately 90% 
bioavailable, with a circulating half-life around 15 hours. Its contraceptive action is exerted at the 
central (hypothalamic) and peripheral (cervical mucus and endometrium) levels. Levonorgestrel 
(LNG), alone or in combination with ethinyl estradiol (EE), is the most widely employed contra-
ceptive progestin: it is used in combined oral contraceptives, progestogen-only pills, long-acting 
contraceptive implants, intrauterine contraceptive systems and in emergency contraception. It is 
also the steroid of choice for new oral contraceptive regimens aimed at reducing the frequency 
of bleeding episodes. This novel approach, already tried more than 30 years ago, gained interest 
around the year 2000 when surveys of women’s attitudes toward monthly menstrual bleeding 
started to show a major change: more and more women declared that they would welcome a 
hormonal contraceptive method that reduced bleeding episodes to 4, 2 or even 1 per year. At this 
point, while the debate on the significance and “usefulness” of menstruation went on, attention 
focused on new regimens. The first new modality consisted of changing the 7-day medication-free 
interval, either shortening it to fewer than 7 days, or by the administration of low-dose estrogens 
during the interval between packages. Then, continuous administration regimens started to be 
investigated. This, however, did not happen suddenly, since, in specific situations, doctors had 
for years empirically utilized various continuous administration regimens. The first extended-
cycle oral contraceptive regimen introduced in clinical practice is an 84-day regimen that results 
in bleeding only 4 times a year. A commercial product specifically packed for continuous use is 
now available in Europe and contains 30 µg EE and 150 µg LNG. In a variation of this regimen, 
after administration of the same combination for 84 days, women are given 7 pills containing 
10 µg EE. A 6-monthly regimen has also been tested in a small study using EE 20 µg plus LNG 
100 µg taken with and without a hormone-free interval. Women in the continuous group reported 
significantly fewer bleeding days requiring protection and were more likely to have amenorrhea; 
in addition they also reported significantly fewer days of bloating and menstrual pain. A yearly 
regimen is now being developed. Each pill of this novel formulation contains EE 20 µg and LNG 
90 µg to be taken continuously for 364 days (13 cycles) per year. A phase III trial has now evalu-
ated safety, efficacy and menses inhibition. At the end of the 1-year trial amenorrhea was present 
in 58.7% of the women and a complete absence of bleeding in 79.0%. Overall, the number of 
bleeding and spotting days per pill pack declined with time and adverse events and discontinua-
tions were comparable to those reported for cyclic oral contraceptive regimens.
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Introduction
The short, but intense history of hormonal contraception is 
usually reconstructed chronologically, from the fundamental 
discoveries in reproductive physiology at the turn of the 
19th century that set the stage (eg, see1–3), to the synthesis 
of various generations of progestins (eg, see4,5).
Today, however, it is possible to redesign in a logical 
fashion the physiological and pharmacological paths that 
led to the present variety of methods; the starting point for 
such a “new history” is the discovery by O’Malley and his 
group of estrogen and progesterone receptors (ER, PR).6 The 
reason is simple: synthetic progestins belong to the large 
family of progesterone receptor ligands and they represent 
the agonists within the group of compounds known today as 
selective progesterone receptor modulators, or SPRMs. This 
family includes pure agonists, such as progesterone itself and 
all synthetic progestins and, at the other end of the spectrum, 
pure antagonists. The so-called “true SPRMs” have mixed 
agonist-antagonist properties and occupy an intermediate 
position in the spectrum.7
In vivo, SPRMs exert clinically relevant tissue-selective 
effects on various progesterone target tissues and these 
effects may differ depending on the biological action 
studied.8,9 This feature has an important clinical applica-
tion, since all receptor modulators bind to more than one 
receptor: for instance, progesterone antagonists bind to the 
antiglucocorticoid receptor,10 whereas synthetic progestins 
may bind to one or more steroid receptors depending on their 
structure.5 This means that, in selecting a hormonal contra-
ceptive for an individual woman, a physician should guide her 
choice by pointing out the metabolic and pharmacodynamic 
profile of different compounds, thereby helping the woman 
in the selection of the product with the most favorable 
characteristics.
It is for this reason that, in reviewing available clinical 
data on the contraceptive modality known as “continuous 
daily administration” of combined oral contraceptives 
containing levonorgestrel, one must start summarizing its 
metabolic characteristics and biological action.
Norgestrel and levonorgestrel
The progestational steroid norgestrel was synthesized and 
tested between 1960 and 1965 through an international 
cooperation between Wyeth (Madison, NJ, USA) and Schering 
(today Bayer-Schering Healthcare, Berlin, Germany);11 its 
chemical structure is (±)-13βethyl-17β-hydroxygon-4-en-
3-one, identifying it as a derivative of gonane (a theoretical ste-
roid skeleton molecule not existing in nature) (see Figure 1).
It is a mixture of two “enantiomers,” a particular form 
of stereoisomers that are mirror images of each other and 
are identical in all their physical properties, with the excep-
tion that they rotate the plane of polarized light in opposite 
directions. To distinguish between the two enantiomers the 
chemical classification that considers the effect of polarized 
light, assigned the prefix (d), or the sign (+) to the dextro-
rotatory form, whereas the prefix (l) or (–) was given to the 
levo-rotatory one; finally the racemic mixture was designated 
as (dl) or (±) norgestrel. Another classification, however, 
based exclusively on the absolute configuration of a given 
compound, defines enantiomers as (d) if they have the same 
configuration as carbon-10 of cholesterol and as (l) (both in 
italics) if they possess the opposite configuration.12 Only one 
of the two enantiomers is biologically active and this active 
form was initially designated as “d-norgestrel” because only 
the d(-) form, contained in 50% of the racemate, is biologi-
cally active; later, however, chemists insisted that the active 
compound be designated as “l-norgestrel” (in italics) because 
the absolute configuration must prevail.13
In view of the fact that, ever since it became possible to 
separate the two enantiomers, only the active form has been 
utilized, it quickly became clear that the chemically correct 
nomenclature could cause confusion among clinicians; for this 
reason, the World Health Organization, Special Programme 
of Research in Human Reproduction (WHO-HRP) recom-
mended that the active levo-rotatory enantiomer of the 
racemic mixture be designated as levonorgestrel (LNG), or 
d(-)l-17β-hydroxy-17α-ethinyl-13β-ethyl-4-gonen-3-one.
Pharmacodynamics of levonorgestrel
The pharmacodynamics of progestogens vary a great deal 
depending on the compound and the route of administration. 
In terms of ovulation inhibition, the most potent progestin 
available today is gestodene, with a daily ovulation-inhibiting 
dose of 40 µg.4
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Figure 1 Norgestrel: 8R,9S,10R,13S,14S,17S-13-ethyl-17-ethynyl-17-hydroxy- 1, 2, 6, 7, 
8, 9, 10, 11, 12, 14, 15, 16-dodecahydrocyclopenta[a]phenanthren-3-one.Patient Preference and Adherence 2009:3 133
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Relative potencies of the most widely utilized progestins 
are shown in Table 1. They have been classified as belonging 
to several different “generations,” as shown in Figure 2.
When taken orally, LNG is rapidly absorbed, is not subject 
to a “first-pass” effect and is approximately 90% bioavail-
able with a circulating half-life around 15 hours.12 After oral 
ingestion of 150 mg, peak plasma levels around 2 ng/mL are 
obtained between 1 and 3 hours, but LNG is still detectable 
in circulation at 48 hours. Its LD50i is 5000 mg/kg.14 When 
circulating, 47.5% is bound to sex hormone binding globulin 
(SHBG), 50% to albumin, while 2.5% is unbound.15 When 
bound to progesterone receptor in the hypothalamus, levo-
norgestrel is capable of slowing gonadotropin releasing 
hormone (GnRH) pulse release, quenching the pre-ovulatory 
luteinizing hormone (LH) surge. Eventually, this phenom-
enon results in ovulation inhibition.16
As already mentioned, like every other progesterone agonist, 
it binds to several steroid receptors. Its in vitro relative binding 
affinities are:16
•  for the progesterone receptor, 323% that of progesterone;
•  for the androgen receptor, 58% that of testosterone;
•  for the mineralocorticoid receptor, 17% that of aldosterone;
•  for the glucocorticoid receptor, 7.5% that of cortisol;
•  for the estrogen receptor, 0.02% that of estradiol.
Mechanism of contraceptive action 
of levonorgestrel
All contraceptive progestins possess a double mechanism 
of action: at the central and at the peripheral level, although 
the relative importance of a particular mechanism in ensur-
ing proper contraceptive protection depends on the route of 
administration.4
Taking into account the synergistic action of the estrogen, 
when combined with 30 to 35 µg of ethinyl estradiol (EE) 
levonorgestrel can block fertility by inhibiting ovulation at 
the daily oral dose of 60 µg (corresponding to peak plasma 
levels of approximately 1 ng/mL). This inhibitory action is 
mainly exerted at the hypothalamic level where, physiologi-
cally, progesterone decreases the number of LH pulses.16,17 
At level of the endometrium, when given orally, LNG 
produces an inactive or atrophic endometrium; however, 
after discontinuation of hormonal exposure, there is a rapid 
return to normal endometrial cycling.18 A different picture 
appears when LNG is delivered directly to the uterine cavity; 
in this case there is extensive decidualization of endometrial 
stromal cells, atrophy of the glandular and surface epithelium 
and changes in vascular morphology (suppression of spiral 
artery formation and presence of large, dilated vessels). There 
is also modulation of local mediators regulating endometrial 
function.19 In addition, local delivery of LNG seems to over-
power the priming effect of endogenous estradiol (E2) and 
in fact, circulating levels of estradiol are within the same 
range, irrespective of whether women are menstruating or 
amenorrheic, pointing to a purely local effect of LNG that 
cannot be influenced by E2.20
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Figure 2 The “Progestogen Tree.”
Abbreviations: CMA, chlormadinone acetate; CPA, cyproterone acetate; 
DNG, dienogest; DrSP, drospirenone; DSG, desogestrol; GST, gestodenes; MGA, 
megestrol acetate; LNG, levonorgestrol; MPA, medroxyprogesterone acetate; NeTA; 
norethindrone acetate; TMG, trimegestone 
Courtesy Prof.   A Genazzani, University of Pisa, italy.
Table 1 Biological activity of different progestogens, using two 
different tests
  Ovulation 
inhibiting dose 
(mg/die)
Endometrial 
transformation 
(mg/cycle)
Progesterone 10 60
Dihydrogesterone 30 140
MPA 10 80
Lynestrenol 2 70
Chlormadinone ac 1.5 20–30
Cyproterone ac 1 20
Noretisterone 0.5 100–150
Norgestimate 0.2 2
Desogestrel 0.06 6
Levonorgestrel 0.05 7
Gestodene 0.04 2
Abbreviations: MPA, medroxyprogesterone ac.Patient Preference and Adherence 2009:3 134
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A different local action is evident even when LNG is 
administered at doses that do not constantly inhibit ovulation; 
under such circumstances a progestin can still remain effec-
tive as a contraceptive by acting at the level of the cervical 
mucus, by significantly decreasing the amount, ferning 
and spinnbarkeit of cervical mucus, while at the same time 
increasing viscosity. Under the effect of progestins, cervical 
mucus scores do not exhibit the normal mid-cycle peak, cervi-
cal mucus receptivity to sperm is lowered, sperm penetration 
in cervical secretion is inhibited and the ovulatory peak of 
the karyopknotic index of vaginal cytology is suppressed. 
Finally, when the mucus is observed by scanning electron 
microscopy, it resembles that seen at the end of pregnancy 
or during menopause.4 After insertion of subcutaneous 
LNG-delivering implants (Norplant) cervical mucus score 
decreases within one week, indicating the profound effect 
of LNG on cervical mucus, even in the event of possible 
ovulation.21
Levonorgestrel-containing 
hormonal contraceptives
Levonorgestrel is the most widely utilized contraceptive 
progestin, alone or in combination with EE. Marketed for the 
first time in the 1960s, LNG can be found today in combined 
oral contraceptives (COC), progestin-only pills, long-acting 
contraceptive implants, intrauterine contraceptive systems 
and in the most widely utilized emergency contraceptive 
modality. A list of marketed preparations containing LNG 
is presented in Table 2.
A remarkable feature of products listed in Table 2 is 
the progressive decrease in dosage that took place in COCs 
containing LNG and EE. This reflects efforts to minimize 
adverse reactions due to either the progestin or the estrogen 
component of the pill.
In this connection, when COCs containing the so-called 
third-generation progestins (desogestrel, gestodene and norg-
estimate) were first marketed, the pharmaceutical industry 
stressed their metabolic “neutrality” and, for a period of time, 
it looked as if these COCs would eventually replace those 
containing LNG.
Then, in 1995, a WHO-sponsored study comparing 
risk  of  venous  thrombo-embolism  (VTE)  with 
second- and third-generation progestins22 found a doubling 
of the risk of VTE in users of COCs containing third-generation 
compounds. A subsequent meta-analysis conducted by 
Kemmeren et al.23 established a relative risk of VTE of 1.7 for 
use of COCs with third- versus second-generation progestins. 
It is important to recall that an increased risk of VTE in women 
using COCs has been reported since 196924 and is today 
accepted as a fact, since it has been documented in all large 
studies conducted since then; the odds ratio (OR) of VTE is 
about four for any COC use.25 This finding led to renewed 
interest in oral contraceptives containing LNG to the point that 
this progestin was selected as the compound to be utilized in 
the majority of studies of new administration modalities aimed 
at reducing the number and duration of menstrual episodes.
Several reasons can be cited for this choice: a long, 
successful clinical experience with levonorgestrel has docu-
mented its safety; in the US (where experience with new 
progestin molecules is much more limited than in Europe) 
randomized studies have shown that LNG-containing 
products have better bleeding patterns than those containing 
norethisterone;26–28 and in Europe, the controversy over the 
above-mentioned increase in VTE with newer progestins has 
not yet been resolved.
Effectiveness
Attitudes towards menstruation
When, in the 1950s and 1960s, Pincus and his team developed 
the first hormonal contraceptive, its administration schedule 
Table 2 Hormonal contraceptives containing norgestrel or 
levonorgestrel
Combined oral contraceptives
  Monophasic
  NGS 500 µg + ee 50 µg
  NGS 500 µg + ev 2 mg
  NGS 300 µg + ee 30 µg
  LNG 250 µg + ee 50 µg
  LNG 125 µg + ee 50 µg
  LNG 250 µg + ee 30 µg
  LNG 150 µg + ee 30 µg
  LNG 100 µg + ee 20 µg
  Phasic
  LNG 50/150 µg + ee 50 µg
  LNG 20/150 µg + ee 30/40 µg
  LNG 50/75/125 µg + ee 30/40/30 µg
Progestin-only pills
  LNG 75 µg, daily without interruption
Subcutaneous implants
  Norplant 1
  Norplant 2 (Jadelle)
  Sinoimplant 1
  Sinoimplant 2  
Abbreviations: ee, ethinyl estradiol; ev, estradiol valerate; NGS, norgestrel; LNG, 
levonorgestrel.Patient Preference and Adherence 2009:3 135
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was selected purely for the convenience of women, although, 
as early as 1958, Pincus wrote that, with hormonal contracep-
tives, “a cycle of any desired length could presumably be pro-
duced.”29 In spite of this, for 50 years, with the exception of 
a small number of subjects like young athletes, women were 
happy with their “artificial menstruations” coming at regular 
28-day intervals, because the belief that “menstruating once a 
month is good for you” remained part of most cultures around 
the world. This reality constituted, at least initially, a major 
stumbling block in modifying the administration schedule 
to decrease the number of yearly bleeding episodes, since 
it was assumed that, for a majority of women word wide, a 
contraceptive method resulting in fewer bleeds or amenor-
rhea would be poorly acceptable. Even half a century ago, 
however, some women felt that artificially decreasing the 
frequency of bleeding would eliminate the adverse symp-
tomatology that sometimes precedes or is associated with 
it. Therefore, at least for them, new contraceptive regimens 
reducing the number of annual menstrual episodes down to 
one may be a welcome development. With time, at least in 
industrialized countries, their number steadily grew till it 
seemed large enough to warrant attention by the pharma-
ceutical industry.
The evolution of attitudes  
towards menstruation
The report of a recent ESHRE (European Society of Human 
Reproduction and Embryology) Capri Meeting30 reminds us 
that periodic vaginal bleeding from the uterus is characteristic 
of humans, old world primates and a small number of other 
mammals. Bleeding results from shedding of the endometrial 
lining of the uterus at the end of a non-fertile ovarian cycle 
and is conditioned by the presence of uterine spiral arterioles; 
Finn31 was the first to speculate that, in species that menstru-
ate, a degree of decidualization of the endometrium during the 
luteal phase occurs even in the absence of an embryo and that 
endometrial shedding can occur only from decidual tissue.
Whatever the physiological mechanisms involved, men-
struation carries a series of clinical consequences that range 
from a minor inconvenience, to a major health concern for those 
who suffer from menstrual disorders and health conditions 
that are aggravated during their menstrual cycle.32 It has been 
calculated that between 20% and 40% of women consider 
their cyclic bleeding as a negative experience, often leading to 
impairment in the conduct of even ordinary business.33
Apart from clinical effects, in every society menstruation 
is surrounded by customs and traditions, with a wide range of 
reactions by individual women, as well as society as a whole, 
to an event that, throughout the ages, has been given positive 
and negative connotations. For instance, menarche, the onset 
of menses at puberty, is considered in some cultures as a 
public event, with festivities celebrating the onset of fertility 
and a sign of the transition from girlhood to womanhood. In 
other cultures, however, menstruating women are considered 
unclean, dangerous and even poisonous. These contrasting 
reactions represent the ambivalent attitudes of society and 
individual women to menstruation.32,34
Positive features of menstrual bleeding
Traditionally there are two main reasons why women believe 
it is important to bleed at monthly intervals; these motives 
have been thoroughly discussed by O’Grady.34
The first is that with menstrual blood women eliminate 
both retained fluid and “body impurities” and, in acceptance 
of that principle, Hippocrates stated that: “menstruation was 
designed to cleanse women of bad humors.” During the Roman 
times, Galen proposed that if menstruation is the natural means 
by which a body cures itself of ills, an ailing person may be 
treated by a physician-initiated blood-letting.35
It seems that prejudices and misconceptions about men-
strual flow, associating it with something “impure” or even 
“dangerous” to be eliminated from the body, have been 
present in every culture across the globe. This is reflected in 
religious practices requiring “purification” after a menstrual 
bleeding. For instance, Orthodox Jewish women observing the 
laws of family purity, abstain from physical contact with their 
husbands from the onset of menses until 7 days after their 
cessation; at this point the woman must take a ritual bath, after 
which she may resume physical and sexual relations with her 
husband.36 In the Islamic tradition, menstruating women are 
exempt from some important religious rites, such as ritual 
prayers, fasting, and the pilgrimage to Mecca. However, 
whereas sexual intercourse is prohibited during menses, all 
other forms of physical contact between husband and wife, 
for example, hugging and kissing, are allowed.37
As pointed out by O’Grady,34 it is possible that the old idea 
of “impurities” or even “toxic agents” present in menstrual 
blood might have been reinforced by the physical discomfort 
that often precedes and accompanies menses. For the modern 
and educated women these misconceptions are almost com-
pletely outmoded, although in individual cases, old beliefs 
can still act unconsciously, aggravating and even originating 
cases of premenstrual syndrome and dysmenorrhea.
The second main reason for welcoming a monthly bleed 
is represented by the so-called “signal of fertility theory,”38 
according to which the occurrence of menses serves as a Patient Preference and Adherence 2009:3 136
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signal: to the woman that she is not pregnant, or infertile; 
and to the man that his female will soon be fertile again. It 
is for this reason that, as already mentioned, when hormonal 
contraception was developed, given the lack of early and 
sensitive pregnancy tests, pill administration was designed 
with pill-taking for 21 days followed by a 7-day free interval, 
to allow periodic bleeding at the time women expected it.39
In discussing the advantages of monthly bleedings, the 
question to be asked is “why do women bleed” and, indeed, 
theories on why menstruations occur and should be welcome, 
abound. From an evolutionary standpoint it seems almost 
obvious that there should be a functional purpose for regular 
menstruation, or it would have neither appeared, nor survived 
during the course of evolution. In 1993, Profet,38 an evolu-
tionary biologist, proposed her “theory of menstruation,” 
according to which bleeding occurs to cleanse the female 
reproductive tract of potentially harmful bacteria that may 
have entered the female reproductive tract with sperm. These 
would be neutralized by the active presence in menstrual 
blood of macrophages; in her view, “menstruation func-
tions to protect the uterus and oviducts from colonization 
by pathogens.” From her perspective, cessation of menses 
would be harmful to a woman’s health rather than beneficial. 
This theory did not go unchallenged, with two opposite argu-
ments being put forward: some argued that, on the contrary, 
menstrual blood may represents an ideal pabulum for sexually 
transmitted micro-organisms and that a woman is more sus-
ceptible to vaginal infections during menstruation than at any 
other time in her cycle.40 Houppert, from studies conducted on 
a variety of reproductive tract conditions (from toxic shock 
syndrome, to infertility and endometriosis), concluded that 
these ailments may be, at least in part, caused by trace levels 
of dioxins found in most tampons and pads. According to 
this hypothesis, modern “management” of menstruation may 
in fact interfere with a natural immune process.41 Adding to 
this, Strassmann42,43 suggested that the function of endome-
trial cyclicity is energy savings: since endometrial function 
is temporally restricted to when fertilization occurs, it would 
be more costly to sustain this tissue when it is not needed, 
than to regenerate it in each cycle. Thus, blood loss is only a 
side-effect. She has calculated that “endometrial economy” 
preserves the metabolic equivalent of 6 days’ worth of food 
for women.
Negative aspects of menstruation
Nowadays, more and more people believe that menstruation 
is simply the sign that the process of reproduction has failed 
and, for the sake of reproductive efficiency, this process has 
to be repeated month after month, until a successfully nested 
fertilized egg starts to develop.35 If this is true, the main rea-
sons for considering menstruation as a positive sign, is that 
it takes place when pregnancy does not. However, this argu-
ment may be utilized to reach very different conclusions.
Some, like Coutinho and Segal35 have gone as far as 
to define regular menstruation as “unnatural,” since in the 
early times, “young women were either pregnant or lactat-
ing almost continuously.” In this respect, it has been calcu-
lated that, from the days of primitive foraging societies to 
the 20th century, the mean number of menstrual bleeds a 
woman would experience during her fertile age, increased 
from 160 to 450.44 Therefore, “from a medical point of view, 
menstruation has no beneficial effects for anyone, and for 
many women it is harmful to their health.”45
This means that menstruation has been viewed as 
“unhealthy” both from a medical (Houppert) and an anthro-
pological (Coutinho and Segal) viewpoint. Reviewing all 
these data, O’Grady34 concluded that “it may be less that 
menstruation ‘causes’ the onset of infectious diseases … 
than that our ‘treatment’ of menstruation interferes with a 
natural immune process.”
It is beside the scope of this review to analyze in depth the 
origin and meaning of menstruation. Clearly, the issue has 
not yet been settled to the point that Emily Martin46 believes 
that, to this day, normative paradigms continue to present 
male functions as the norm, with differences observed in 
females seen as aberrations from a male “norm”: to people 
following this “philosophy” menstruation cannot be a posi-
tive phenomenon.
Bleeding irregularities
While sociologists, gynecologists and anthropologists may 
differ in their appraisal of menstruation, everyone agrees 
that irregular bleeding (and more specifically heavy bleed-
ing) is a major public health problem, besides being one of 
the main reasons why women discontinue certain hormonal 
methods of contraception (specifically, those containing only 
a progestin). Indeed, every year some 5% of all women in 
US aged 30 to 49 years consult their physician for bleeding-
related problems.47
As pointed out in the already mentioned ESHRE 
document,30 menstrual disorders significantly interfere 
with the quality of life and each year they cause the loss of 
millions of work-days with enormous costs being incurred 
for treatment. Bleeding irregularities are more common near 
the beginning and end of the fertile life, due to the frequent 
occurrence of anovulatory cycles.Patient Preference and Adherence 2009:3 137
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Given these facts, many women have welcome COCs, a 
modality capable or guaranteeing cyclic withdrawal bleeding 
to the vast majority of users. In addition, a specific adminis-
tration schedule that allows less frequent bleeding is likely 
to be welcome, at least by women troubled by menstrual 
disorders.
Acceptability of amenorrhea 
in different cultures
As shown above, until recently a majority of health profes-
sionals have safely assumed that women would prefer to 
menstruate at regular monthly intervals and, from the early 
days of hormonal contraception,48 a contraceptive method 
is to be considered ideal only if it allows regular monthly 
withdrawal bleedings; as a consequence, amenorrhea had to 
be considered an undesirable side effect. This concept was 
reinforced by large surveys of women’s attitudes towards 
menstruation carried out during the 1970s by the WHO-
HRP. These investigations concluded that the proportion of 
women who were prepared to use a method of contraception 
causing amenorrhea, ranged from 47% in UK to only 10% 
in Pakistan.49
In spite of the widespread desire for regular menses, 
progestin-only contraceptives (such as depot medroxy-
progesterone acetate, or DMPA), which have been credited to 
cause “menstrual chaos,” are perfectly acceptable to women 
in a number of developing countries.50,51
Clearly, the cultural context plays an important role 
even within the same country. For instance, a study carried 
out in the US showed that black women are generally more 
conservative and significantly fewer black than white women 
consider acceptable a contraceptive modality abolishing 
monthly bleeds. Indeed, two thirds of white women did not 
like monthly bleeds and would prefer bleeding-free inter-
vals ranging from 90 days to complete amenorrhea. Among 
these women, 40% were ready to consider using a hormonal 
contraceptive that stops menstruations altogether, with the 
other 60% either unwilling or undecided.52
The existence of important attitudinal differences between 
women of different cultures has been highlighted in several 
multinational, comparative studies. A first, pioneering survey, 
published in 200353 involved women in Nigeria, South Africa, 
Scotland and China. Only among black women in Africa 
did the majority like having periods. In the other groups 
most women disliked periods, which were “inconvenient” 
and associated with menstrual problems. For this reason, 
these women would be willing to try a contraceptive that 
induces amenorrhea. In another study comparing attitudes 
towards menstruation in the US, Brazil and Germany, when 
asked about their ideal non-bleeding interval, approxi-
mately one-third of the respondents in the US and Brazil 
declared to prefer not to bleed at all, whereas less than 10% 
of women sampled in Germany favored this option. In all 
three countries, the proportion of women who indicated a 
preference for bleeding every 6 months was substantially 
lower than the corresponding proportion of women who 
preferred to bleed every 3 months. In all countries women 
felt that the most common positive features of having 
menses were: being assured of not being pregnant; feeling 
healthier; and feeling lighter. Conversely, the most common 
negative features of menstruation were cramps, bad mood, 
inconvenience before and during menses (eg, premenstrual 
syndrome).54
Studies involving only European women show a trend 
towards a more positive attitude vis-à-vis amenorrhea. For 
instance, in the Netherlands a survey published in 1999 
indicated that only around 30% of the women wanted to 
have periods every month; about 25% did not want to have 
periods any more and the rest wanted to modify the frequency 
of their periods to occur at 3- 6- or 12-month intervals.55 In 
France, only 11% of women involved in a large survey carried 
out in 2005 liked to have their periods every month; 75% 
considered menstruation to be a constraint. When specifically 
asked whether they would take a pill that would prevent them 
from bleeding, 57% responded positively.56 In a study of 
Italian women published in 2006, among 270 women without 
menstruation-related symptoms, more than 50% stated that 
they would like to change the rhythm of their periods, with 
28% wishing longer intervals between bleedings and 29% not 
to have menses at all.57 Contrary to the results obtained in the 
previously mentioned multicenter study54 a survey published 
in 2004 showed that only 26% to 35% of German women 
preferred monthly bleeding, while 37% to 46% wished not 
to have menses at all. Those wishing not to bleed cited, as 
positive outcomes, relief from severe menstrual complaints, 
better hygiene, higher quality of life, and less blood loss. 
Among women preferring regular withdrawal bleeding when 
using a COC, the main reasons for their choice were the fact 
that menstruation is a normal phenomenon, fear of pregnancy, 
fear of infertility and possible adverse effects of continuous 
regimens.58 A more conservative attitude seems to be still 
prevalent among Spanish women: In a just published study, 
among 588 women aged between 18 and 45 years, only 5% 
expressed interest in using a continuous oral contraceptive 
regimen. This percentage increased to nearly 50% in women 
below 25 years.59Patient Preference and Adherence 2009:3 138
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Finally, a survey conducted in Australia more than 20 years 
ago, which evaluated knowledge, attitudes and practices of 
young women concerning menstruation, menstrual protec-
tion and menstrual cycle problems, indicated that the young 
women, as a group, lacked sufficient information about 
menstruation, time of ovulation, menstrual discharge, and 
even the use of tampons. A high proportion (80%) considered 
menstruation to be inconvenient or embarrassing.60
New administration regimens 
for combined oral contraceptives 
containing levonorgestrel
As early as 1977, the group of Roger Short and Malcolm 
Potts showed that reducing withdrawal bleedings to four 
times a year (using an oral contraceptive containing EE 50 µg 
plus lynestrenol 2.5 mg) was both acceptable and effective: 
82% of the women welcomed fewer menstrual bleeds and 
the parallel reduction in menstrual and premenstrual symp-
toms, and many found the tri-cycle regimen easier to follow. 
Menstrual loss was unchanged, or simply reduced in all but 
seven women. Interesting enough, according to the authors, 
“doctors and nurses on the clinic staff were less enthusiastic 
about this regimen than the volunteers themselves.”61
This study, however, remained an isolated attempt for 
more than 20 years, and it was only when developments in 
hormonal contraception produced COCs in which the estrogen 
daily dose had reached the minimum feasible and after the 
introduction of a series of new progestins, that the attention 
of developers switched to novel administration schedules.
Initially, attention focused on changing the 7-day 
medication-free interval and, some 10 years ago, a 24-day 
regimen followed by a hormone-free interval of only 4 days 
was tested and introduced into clinical practice. The first such 
preparation contains EE 15 µg plus gestodene 60 µg;62 others 
followed: one is made up of EE 20 µg plus drospirenone 2 mg.63 
The second contains EE 20 µg plus drospirenone 1 mg.64
More recently, however, new options have been consid-
ered to decrease the frequency of free intervals or to eliminate 
them altogether.39
After Thomas and Ellertson65 stated in 2000 that it might be 
time to give women the choice of “if and when to menstruate,” 
Andrist et al66 added that, since pharmacological methods to 
safely “manipulate” menstrual cycles now exist, it is high time 
to investigate new options. As already pointed out, in specific 
situations various continuous administration regimens have 
been empirically recommended by doctors: for instance, in 
young athletes, or in the event of marriage, the 21-day regimen 
has been extended to permit the withdrawal bleeding to occur 
away from the event. In addition, extended pill use (with or 
without interruption) has also been advocated as a maintenance 
treatment for endometriosis-associated pelvic pain in women 
not wishing to become pregnant,67,68 to avoid menstruation-
associated symptoms, such as migraine headache69 and 
premenstrual syndrome.65 In addition, Martin-Johnston et al70 
found that there is an increased number of reproductive age 
women at risk for thrombocytopenia and, they too, would 
benefit from menses suppression.
Data on continuous administration regimens began 
to appear with the new millennium and in 2001, Miller71 
reported the first study on the continuous daily administra-
tion of LNG (100 µg) and EE (20 µg) for the “elimination of 
menses.” No pregnancies were observed in 94 subjects.
Trimonthly regimens
The first formulation specifically packed for continuous use 
was marketed in the US under the trade name of Seasonale® 
by Duramed Pharmaceuticals Inc., a subsidiary of Barr 
Pharmaceuticals, Montvale, New Jersey. It contains 30 µg EE 
and 150 µg LNG. The package comes in a 3-monthly supply. 
Women take one active pill per day for 84 days (12 weeks) 
and then take an inactive pill for 7 days.72 This regimen 
allows a reduction from 13 to 4 bleeding episodes per year; 
however, during the first 8 or 9 months of use, women taking 
the COC continuously are about twice as likely as those using 
conventional regimens to experience breakthrough bleedings. 
Two clinical trials have evaluated this new regimen.73,74 In 
the second, the longer-term study, overall, 189 women were 
enrolled from 27 clinical sites and treated with Seasonale®. Of 
these women, 103 (54%) were from the first study, whereas 
the remaining women had previously been assigned to one 
of the other COC therapies evaluated in that trial. As this 
was primarily a long-term safety study, no formal efficacy 
evaluation was planned other than a simple calculation of 
the proportion of treated patients who became pregnant. At 
any rate, no pregnancy was reported.
A variation of this regimen, named Seasonique® consists 
of a continuous administration of the same combination for 
84 days, followed by 7 pills containing 10 µg EE instead of a 
pill-free interval. This preparation has been tested for safety 
and efficacy in some 700 women.75 A Pearl Index of 1.27 was 
calculated, with adverse reactions causing the discontinua-
tion of 16% of the subjects. Withdrawal bleeding occurred 
in the majority of cases, in spite of the presence of low dose 
estradiol during the interval period; this was attributed to the 
progestin withdrawal. This regimen may be an option for Patient Preference and Adherence 2009:3 139
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women who experience bleeding/spotting during the use of 
an extended, 3-monthly cycle regimen
Other combinations are now being tested: after the 
introduction of a COC containing EE 20 µg and drospirenone 
2 mg as a 21-day regimen this combination is now being tried 
for possible utilization for 120 days without interruption. 
Preliminary data indicate a positive effect on the so-called 
pre-menstrual dysphoric disorder and on endometriosis-
associated pain.76,77 Given its positive profile, this new 
“trimonthly pill” will soon become available in Europe.
Data are now accumulating on women perception after 
taking extended-cycle oral contraceptives. A survey conducted 
in the US in 2002, found that 41% of women of fertile age 
(18 to 49 years), would prefer never to menstruate, with the 
highest preference in the 40- to 49-year-old group. Only 29% 
of the women felt that it was necessary to menstruate once 
per month and, when asked why they preferred this option, 
the reply was that bleeding serves as confirmation that a 
woman is not pregnant.78 In a second, recent survey, 80.5% of 
currently menstruating women preferred one or more changes 
in bleeding pattern (eg, less pain, shorter and lighter bleeds, 
or amenorrhea). In addition, the majority of women in all age 
groups preferred to have longer intervals between bleeding.79
Another study focused on adolescents and found that an 
overwhelming majority of them (96.6%) view unexpected 
bleeding negatively; therefore, extended regimens seem 
particularly attractive to this group of women.80 Finally, 
even the attitude of health professionals who, in the past 
have been found to be more conservative than their patients, 
seems to be changing. When, in 2006, Sulak et al surveyed a 
group of health-care professionals (primary care physicians, 
obstetrician/gynecologists, nurse practitioners and physician 
assistants), about their attitudes toward prescribing extended-
cycle COCs, a total of 81% of those asked reported that they 
have recommended extending the number of active pills in 
the traditional oral contraceptive 21/7 regimen.81
In addition to acceptability, Schwartz et al have also 
addressed the question of cost-effectiveness of extended 
cycle regimens. They found that the economic savings for 
patient out-of-pocket expenses from decreased sanitary 
product usage, as a result of nine fewer withdrawal bleeding 
episodes, is offset by the cost of three extra packages of 
COCs. They concluded that the tri-monthly schedule may 
be cost-effective for women with menorrhagia.82
Six-monthly regimens
In 2003, Kwiecien et al published the first, small study aimed 
at evaluating in a comparative fashion bleeding patterns and 
acceptability of EE 20 µg plus LNG 100 µg taken with and 
without a hormone-free interval. Thirty-two women were 
randomized to six 28-day cycles or 168 days without a 
pill-free interval. Women in the continuous group reported 
significantly fewer bleeding days requiring protection and 
were more likely to have amenorrhea, as shown in Figure 3. 
There were no pregnancies and, given the small group of 
women involved, the observed decrease in total bleeding 
days did not reach statistical significance. However, women 
in the continuous group reported significantly fewer days of 
bloating and menstrual pain.83 The authors concluded that 
both methods of administration have equivalent subjective 
acceptability.
Annual regimen
Following the already mentioned first trial by Miller,71 Miller 
and Hughes84 published the results of a new comparative 
study in which 79 women were randomized to either classic 
28-day cycles (21 active pills and a pill-free week) or to 
12 cycles (336 days) of continuous use of a preparation 
containing LNG 100 µg and EE 20 µg. A first important 
outcome of the study was the difference in continuation rates: 
70% (28 subjects) for the 28-day cycle and 82% (71) for the 
continuous-use subjects. With continuous use, 49%, 68% 
and 88% of the women reported no bleeding during cycles 
2, 6 and 12, respectively, while amenorrhea or infrequent 
bleeding was present in 68% of continuous users during 
cycles 1 to 3 and increased to 88% during cycles 10 to 12. 
Spotting initially increased in continuous users, but reduced 
over time, and by 9 months was less than the spotting reported 
by cyclic users. No pregnancy was reported and the incidence 
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Figure 3 Percentage of subjects reporting no bleeding in each treatment cycle. 
Asterisks indicate significant difference (p = 0.05) within a cycle.
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of adverse events, blood pressure, weight, and hemoglobin 
findings was similar between groups.
Once the acceptability of “no bleeding” regimens was 
ascertained, developers focused their attention on the con-
tinuous administration over 1 year of a LNG-containing 
pill. This resulted in the development and clinical testing 
of a not-yet-marketed formulation meant for women who 
would like to avoid bleeding altogether. Each pill contains 
EE 20 µg and LNG 90 µg and is to be taken continuously 
for 364 days/year. It is distributed in packages containing 
28 tablets. It has been given the trade name of Lybrel®, and 
is being developed by Wyeth Corp. (Madison, NJ, USA). 
Recently, a study was conducted to evaluate the safety, 
efficacy and menses inhibition with this continuous daily 
regimen in 2402 women, of whom 921 completed the study, 
while 2134 took the preparation for at least 1 month. The pro-
tocol included two sub-studies to assess cycle-related symp-
toms and endometrial histology. A first paper was recently 
published summarizing the safety and efficacy results of the 
phase 3 trial and evaluated menses inhibition. At the end of 
the 1-year trial (Pill Pack 13), results showed that amenorrhea 
was present in 58.7% of women and a complete absence of 
bleeding in 79.0%. This terminology may be confusing, since 
usually amenorrhea is defined as the complete absence of 
bleeding. Overall, the number of bleeding and spotting days 
per pill pack declined with time; adverse events and discon-
tinuation rates were comparable to those reported for cyclic 
COC regimens, except for higher rates in effects related to 
uterine bleeding. The Pearl Index method failure was 1.26, 
and user failure was 0.34. While on Pill Pack 13, 58.7% of 
subjects reported amenorrhea and 79.0% reported absence 
of bleeding. Overall, the number of bleeding and spotting 
days per pill pack declined progressively. Adverse events 
and discontinuations were comparable to those reported for 
cyclic oral contraceptive regimens, except for higher rates 
in those related to uterine bleeding. Authors concluded that 
the continuous administration of the LNG/EE pill indicates 
a good safety profile and efficacy similar to that of cyclic 
COCs: The regimen continuously inhibited menses, increased 
the incidence of amenorrhea over time and, except for a 
subset of women, decreased the number of bleeding and 
spotting days.85 Results of the morphological paper are also 
available for 93 volunteers who completed at least 6 pill 
packs and for whom a baseline biopsy was available. Before 
treatment, 60% had an endometrial biopsy with findings clas-
sified as “weakly proliferative or proliferative”. At the last 
visit, 52% of the subjects had an endometrium categorized as 
“other,” which included primarily an “inactive” or “benign” 
endometrium. No hyperplasia or malignancy was observed 
during the study.86 This study indicates a good endometrial 
safety profile.
Interestingly enough, the availability of  this new 
administration schedule provoked a heated debate even 
before the combination had a chance to be marketed. Indeed, 
on April 20, 2007, The New York Times ran an article by 
Stephanie Saul pointing to the ambivalence women feel 
about taking a drug that will suppress monthly bleedings. 
She spoke of a “complex love-hate relationship” women have 
with their period, something denied by the manufacturer. The 
company collected data in the US through a questionnaire 
and found out that women’s interest toward this pill depended 
on a personal approach to monthly periods. Indeed, 50% 
of the women they surveyed said that they welcomed their 
periods as an indicator that they were not pregnant and 25% 
said that their periods were a natural part of womanhood. In 
contradistinction, two-thirds of the same women supported 
the idea of avoiding monthly bleeds.87 The debate heated 
up when some feminist groups accused the manufacturer 
of misogyny. Pretty soon the Web filled-up with activists 
arguing that women may wish to get rid of menstruation to 
please their partners, or to look more like men.
What seems to have been lost in the debate is the fact that 
this particular pill will be taken only by women who wish to 
become amenorrheic; under the circumstances, its availability 
cannot possibly be considered as “violence” against women’s 
attitudes or beliefs.
Comparison between continuous 
and cyclic administration
A recent Cochrane review analyzed data on cyclic 
versus continuous administration of LNG-containing 
COCs.88 It compared contraceptive efficacy, compliance, 
continuation, satisfaction, bleeding profile and menstrual 
symptoms of combined oral contraceptives with continuous 
regimens (ie, 28 days of active pills). Interestingly, not 
only contraceptive efficacy but also compliance were similar 
between groups. Also, overall discontinuation, and that for 
bleeding problems, were not evenly distributed between the 
two groups. In general, participants reported high satisfac-
tion with both types of regimens. As expected, the group 
with continuous administration had greater improvement of 
menstrual-associated symptoms (headache, genital irritation, 
tiredness, bloating, and menstrual pain).
Lack of sufficient information prevents a true comparison 
between continuous administration regimens and, in 2007, 
Steinauer and Autry stated: “Although we do not have enough Patient Preference and Adherence 2009:3 141
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data to recommend one particular extended cycle regimen 
over another, the use of these new regimens will provide 
women with more options, and almost certainly will improve 
the acceptability and efficacy of hormonal contraception.”89
Conclusions
Continuous daily administration of oral hormonal contraceptives 
containing levonorgestrel and ethinyl estradiol (for 3 or 
6 months, or 1 year) is still in a preliminary stage of clinical 
testing. Indeed, although two 3-monthly preparations have 
been marketed, limited information is available. Nonetheless, 
these new administration schedules seem well accepted by 
women, safe and effective.
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